MINPP1 and hepatocellular carcinoma: In the study reporting these findings, a new tumorigenic axis, HBp/FOXO3a/miR-30b-5p/MINPP1, was discovered (39), and it facilitated the regression of HBV-positive hepatocellular carcinoma through a glycolytic bypass that is specific to HBV-associated hepatocellular carcinoma.